Piramal Primes Hospital Injectables Play Via Janssen Products

Piramal is continuing on its acquisitive spree, snapping up a basket of injectable products from Janssen that are expected to give the diversified Indian group a foothold in the $20bn-plus global generic injectable hospital drugs market.